Prialt

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
IB/0077/G	This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.e - Stability of FP - Change to an approved	20/06/2024		SmPC	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	stability protocol A.7 - Administrative change - Deletion of manufacturing sites				
IA/0078	A.7 - Administrative change - Deletion of manufacturing sites	23/05/2024	n/a		
IAIN/0075	A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release	18/10/2023		Annex II and PL	
N/0074	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	25/10/2022		PL	
IA/0073/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or	17/10/2022	n/a		

	starting material/reagent/intermediate - Minor changes to an approved test procedure				
IA/0072/G	This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.c.z - Container closure system of the AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	17/10/2022	n/a		
PSUSA/3142/ 202112	Periodic Safety Update EU Single assessment - ziconotide	01/09/2022	n/a		PRAC Recommendation - maintenance
II/0068	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	23/06/2022	02/08/2022	SmPC, Annex II, Labelling and PL	Increasing evidence based on case reports and observational studies show that ziconotide has a better tolerance profile and provides higher benefits when used carefully with low initiation dose and slow titration using low dose increments in long intervals along with continuous monitoring of drug response. As the result, the SmPC was updated to introduce a reduced posology to allow dosing flexibility and meet individual patients' needs in terms of

					analgesia and adverse events. Moreover, additional risk minimization measures were implemented in the SmPC/PIL due to serious adverse events, including suicide, that can also occur with low starting doses. For more information, please refer to the Summary of Product Characteristics.
IA/0071/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	08/06/2022	n/a		
IAIN/0069	A.1 - Administrative change - Change in the name and/or address of the MAH	24/11/2021	04/07/2022	SmPC, Labelling and PL	
IAIN/0067	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	09/06/2021	04/07/2022	Annex II and PL	
N/0065	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	05/10/2020	04/07/2022	PL	
IA/0066	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -	18/08/2020	n/a		

	Replacement/addition of a site where batch control/testing takes place				
IA/0064/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	03/04/2020	n/a		
N/0063	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	25/02/2020	04/07/2022	PL	
IB/0062/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or	18/02/2020	n/a		

	intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				

	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.d.z - Stability of AS - Other variation				
PSUSA/3142/ 201812	Periodic Safety Update EU Single assessment - ziconotide	11/07/2019	n/a		PRAC Recommendation - maintenance
IA/0061	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	16/05/2019	n/a		
IAIN/0060/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP -	16/05/2019	n/a		

	Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing				
IAIN/0059/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	08/04/2019	18/12/2019	Annex II and PL	
IAIN/0057	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	16/01/2019	18/12/2019	Annex II and PL	
T/0056	Transfer of Marketing Authorisation	08/06/2018	02/07/2018	SmPC, Labelling and PL	
IA/0055/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -	02/05/2018	n/a		

	Replacement/addition of a site where batch control/testing takes place				
N/0054	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	10/11/2017	15/01/2018	PL	
IA/0053/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	24/03/2017	n/a		
II/0052	Update of sections 4.4 and 4.8 of the SmPC in order to amend the information on anaphylactic reactions following post-marketing cases and the relevant PRAC recommendation in conclusion to the assessment of EMEA/H/C/PSUSA/00003142/201512. The Package Leaflet is updated accordingly. Minor additional changes are made to the SmPC. C.I.3.b - Change(s) in the SPC, Labelling or PL	26/01/2017	15/01/2018	SmPC and PL	

	intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH				
II/0050	B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF	10/11/2016	n/a		
IB/0051/G	This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	14/09/2016	n/a		
PSUSA/3142/ 201512	Periodic Safety Update EU Single assessment - ziconotide	07/07/2016	n/a		PRAC Recommendation - maintenance
N/0048	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	27/01/2016	15/01/2018	PL	
IA/0047	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	12/11/2015	n/a		
PSUSA/3142/ 201412	Periodic Safety Update EU Single assessment - ziconotide	09/07/2015	n/a		PRAC Recommendation - maintenance

R/0045	Renewal of the marketing authorisation.	24/07/2014	18/09/2014	SmPC, Annex II, Labelling and PL	The benefit -risk balance for Prialt remains unchanged. Minor updates to the product information to bring it in line with the QRD template were introduced. The renewal is granted with unlimited validity.
PSUV/0044	Periodic Safety Update	10/07/2014	n/a		PRAC Recommendation - maintenance
S/0040	8th Annual Re-assessment	21/11/2013	17/01/2014	SmPC, Annex II and PL	Having reviewed the evidence of compliance with the specific obligations and the data submitted within this annual re-assessment, the CHMP concluded that the benefit risk balance of Prialt in the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia remains positive. As all remaining Specific Obligations were fulfilled, the CHMP agreed that exceptional circumstances should be lifted.
IB/0043/G	This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.4.b - Change in the batch size (including batch	10/01/2014	n/a		

	size ranges) of the finished product - Downscaling down to 10-fold B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products				
IG/0345	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	03/09/2013	n/a		
IAIN/0041	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	21/05/2013	n/a		
IB/0039	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	27/03/2013	17/01/2014	SmPC	
S/0038	7th Annual Re-assessment	19/07/2012	20/09/2012	SmPC, Annex II, Labelling and PL	The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the

					product remains favourable.
IA/0037/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)	15/12/2011	n/a		
S/0034	Annual Re-assessment	21/07/2011	27/07/2011		The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the product remains favourable.
IB/0036	C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH	21/07/2011	n/a	SmPC and PL	
IA/0035	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	08/06/2011	n/a		
II/0033	Change of the vial stoper B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative	23/09/2010	28/09/2010		

	composition - Sterile medicinal products and biological/immunological medicinal products				
S/0032	The CHMP, having reviewed the evidence of compliance with the specific obligations and the safety information submitted by the Marketing Authorisation Holder, concludes that the benefit/risk ratio for the product remains unchanged. The CHMP considered that the Marketing Authorisation for Prialt should remain under exceptional circumstances in view of the pending specific obligation.	22/07/2010	28/07/2010		The CHMP, having reviewed the evidence of compliance with the specific obligations and the safety information submitted by the Marketing Authorisation Holder, concludes that the benefit/risk ratio for the product remains unchanged. The CHMP adopted on 22 July 2010 an Opinion on the annual reassessment of Prialt. A new follow-up measure was agreed upon and the Marketing Authorisation Holder provided a revised Letter of Undertaking dated 9 July 2010 detailing the specific obligation and follow-up measures remaining outstanding. The CHMP considered that the Marketing Authorisation for Prialt should remain under exceptional circumstances in view of the pending specific obligation.
N/0031	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	14/04/2010	n/a	Labelling and PL	
R/0030	Renewal of the marketing authorisation.	22/10/2009	12/01/2010	SmPC	Based on the data that have become available since the granting of the marketing authorization under exceptional circumstances, the CHMP considers that the benefit-risk balance of Prialt remains positive, but considers that its safety profile is to be closely monitored for the following reasons: There is one specific obligation outstanding, the PRIME study which is expected to generate relevant long-term

					safety and efficacy data on the product. The CHMP is also of the opinion that submission of yearly PSURs should continue until concerns identified in relation to the pharmacovigilance system are adequately addressed. Therefore, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time.
N/0029	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	17/09/2009	n/a	PL	
S/0027	Annual Reassessment	23/04/2009	30/04/2009		
IA/0028	IA_01_Change in the name and/or address of the marketing authorisation holder	17/03/2009	n/a	SmPC, Labelling and PL	
IA/0026	IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing	13/02/2009	n/a	Annex II and PL	
N/0025	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	12/02/2009	n/a	PL	
S/0021	Third Annual Reassessment (S/0021)	30/05/2008	25/08/2008	SmPC, Annex II and PL	The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile for Prialt, concluded that the benefit/risk of the product remains unchanged. The CHMP considered that the Marketing Authorisation for Prialt should remain

					under exceptional circumstances in view of the pending Specific Obligation.
IA/0024	IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site	03/07/2008	n/a		
IA/0023	IA_09_Deletion of manufacturing site	24/06/2008	n/a		
IB/0022	IB_37_a_Change in the specification of the finished product - tightening of specification limits	20/05/2008	n/a		
IA/0020	IA_13_a_Change in test proc. for active substance - minor change	19/03/2008	n/a		
IA/0019	IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site	15/02/2008	n/a	Annex II and PL	
N/0017	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	21/01/2008	n/a	Labelling and PL	
IA/0018	IA_05_Change in the name and/or address of a manufacturer of the finished product	28/11/2007	n/a		
S/0009	Annual re-assessment.	24/05/2007	20/07/2007	Annex II, Labelling and PL	The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile for Prialt, concluded that the benefit/risk of the product remains unchanged. The CHMP considered that the Marketing Authorisation for Prialt should remain under exceptional circumstances in view of the pending Specific Obligation.

IA/0015	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	04/07/2007	n/a		
IA/0014	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	04/07/2007	n/a		
IB/0010	IB_13_b_Change in test proc. for active substance - other changes (replacement/addition) IB_38_c_Change in test procedure of finished product - other changes	03/07/2007	n/a		
IA/0016	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	02/07/2007	n/a		
IA/0013	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	02/07/2007	n/a		
IA/0012	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	18/06/2007	n/a		
IA/0011	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	18/06/2007	n/a		
IA/0008	IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing	06/10/2006	n/a	Annex II and PL	
T/0007	Transfer of Marketing Authorisation	14/08/2006	13/09/2006	SmPC, Labelling and PL	The Marketing Authorisation has been transferred from Elan Pharma International Ltd to Eisai Limited.
S/0005	Annual re-assessment.	01/06/2006	28/07/2006	Annex II	The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the Marketing

					Authorisation Holder and having re-assessed the benefit/risk profile for Prialt, concluded that the benefit/risk of the product remains favourable in the approved indication. The CHMP considered that the Marketing Authorisation for Prialt should remain under exceptional circumstanced in view of the pending Specific Obligations. (Post Marketing observational study to evaluate the long-term efficacy and safety of Prialt).
II/0004	This variation refers to an update of the section 4.8 of the Summary of Product Characteristics (SPC) and section 4 of the Package Leaflet (PL) further to the fulfillment of the Follow-Up Measures (FUMs) 004, 005 and 006. Update of Summary of Product Characteristics and Package Leaflet	27/04/2006	31/05/2006	SmPC and PL	The Marketing Authorisation Holder fulfilled the following Follow-up Measures: - FUM 004: "To evaluate the potential development of hyperalgesia following IT administration of ziconotide in the controlled studies (95-001, 96-002 and 301)." - FUM 005: "To integrate the safety data from studies 301, 302, 351 and 352 into the MAA safety data base, and to look at the adverse events in patients taking CNS active drugs." - FUM 006: "To provide efficacy and safety data on the ongoing long-term studies 351, 352 and 501, including the VASPI scores. To establish the correlations between dose increment intervals and efficacy and safety events." Further to the final report analysis on the clinical studies 301, 302, 351, 352 and 501, the MAH applied for an update of the sections 4.8 of the SPC and 4 of the Package Leaflet to reflect the clinical data available on the evaluations of the potential development of hyperalgesia following IT administration of ziconotide in some controlled studies and of the efficacy and safety data on the ongoing long-term studies 351, 352 and 501; the sections 4.8 of the SPC and 4 of the PL were therefore amended according to the adverse event pattern reported in studies 302, 351,

					352 and 501.
IA/0006	IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site	24/05/2006	n/a		
II/0003	This variation relates to an update of sections 4.4, 4.5 and 5.1 of the Summary of Product Characteristics (SPC) to include data from the titration and extension phases of the clinical studies ELN92045-201 and ELN92045-202. The MAH also took this opportunity to include the ATC code in the section 5.1 of the SPC, and to include minor linguistic changes and punctuation errors in the Labelling and Package Leaflet. Update of Summary of Product Characteristics, Labelling and Package Leaflet	23/02/2006	29/03/2006	SmPC, Labelling and PL	The Marketing Authorisation Holder has committed to fulfil the following Follow-up Measure: "To provide the results of formal intrathecal morphine-ziconotide clinical interaction studies (ELN92045-201, ELN92045-202) and submission of a variation to the SPC to account for conclusions from these studies." Further to the final report analysis on the long-term extensions of both studies ELN92045-201 and ELN92045-202, the MAH applied for an update of the sections 4.4, 4.5 and 5.1 of the SPC to reflect the clinical data available on concomitant use of IT opioids and IT ziconotide. The MAH also took this opportunity to include the ATC code in the section 5.1 of the SPC. Minor linguistic changes and punctuation errors in the Labelling and Package Leaflet were also made during this procedure.
X/0002	Change or addition of a new strength/potencyAddition of new strength - 25 mg/ml solution for infusion. Annex I_2.(c) Change or addition of a new strength/potency	26/01/2006	20/03/2006	SmPC, Annex II, Labelling and PL	The new presentation consists in one new strength (25 µg/ml of ziconotide (as acetate salt), solution for infusion), presented in 20 ml vials. The important quality characteristics of the active substance are well-defined and controlled, and the product is formulated, manufactured and controlled in a way that is characteristic for this new strength application. The specifications and batch analytical results indicate a consistent product with uniform clinical performance from batch to batch. The risk/benefit is considered acceptable since the proposed 25 µg/ml solution for infusion is better adapted to the dosing regime and eliminates the need for dilution prior to administration. Apart from the strength, the product is identical to the

					approved 100 µg/ml formulation.
IA/0001	IA_28_Change in any part of primary packaging material not in contact with finished product	11/05/2005	n/a		